107 related articles for article (PubMed ID: 15618958)
1. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML.
Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2005 Feb; 19(2):197-200. PubMed ID: 15618958
[TBL] [Abstract][Full Text] [Related]
2. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.
Andersen MK; Christiansen DH; Kirchhoff M; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2001 May; 31(1):33-41. PubMed ID: 11284033
[TBL] [Abstract][Full Text] [Related]
3. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
5. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
6. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
[TBL] [Abstract][Full Text] [Related]
7. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
8. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia.
Niini T; Kanerva J; Vettenranta K; Saarinen-Pihkala UM; Knuutila S
Haematologica; 2000 Apr; 85(4):362-6. PubMed ID: 10756360
[TBL] [Abstract][Full Text] [Related]
9. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
10. Isodicentric/pseudoisodicentric chromosome 21 amplification in four cases of acute myelocytic leukemia or myelodysplasia.
Viguié F; Aboura A; Bouscary D; Guesnu M; Baumelou E; Dreyfus F; Casadevall N; Tachdjian G
Cancer Genet Cytogenet; 2002 Oct; 138(1):80-4. PubMed ID: 12419591
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21.
Streubel B; Valent P; Lechner K; Fonatsch C
Cancer Genet Cytogenet; 2001 Jan; 124(1):42-6. PubMed ID: 11165321
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
[TBL] [Abstract][Full Text] [Related]
14. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study.
Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2005 Apr; 42(4):358-71. PubMed ID: 15645489
[TBL] [Abstract][Full Text] [Related]
15. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
16. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
17. Complex t(8;13;21)(q22;q14;q22)--a novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Udayakumar AM; Alkindi S; Pathare AV; Raeburn JA
Arch Med Res; 2008 Feb; 39(2):252-6. PubMed ID: 18164974
[TBL] [Abstract][Full Text] [Related]
18. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies.
Moosavi SA; Sanchez J; Adeyinka A
Cancer Genet Cytogenet; 2009 Feb; 189(1):24-8. PubMed ID: 19167608
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia.
Busson-Le Coniat M; Nguyen Khac F; Daniel MT; Bernard OA; Berger R
Genes Chromosomes Cancer; 2001 Nov; 32(3):244-9. PubMed ID: 11579464
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
